Sargent Investment Group LLC Decreases Stake in Cytosorbents Co. (NASDAQ:CTSO)

Sargent Investment Group LLC trimmed its position in Cytosorbents Co. (NASDAQ:CTSO) by 23.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,248,863 shares of the medical research company’s stock after selling 377,384 shares during the period. Sargent Investment Group LLC owned about 2.28% of Cytosorbents worth $1,136,000 at the end of the most recent reporting period.

Separately, Atomi Financial Group Inc. purchased a new position in Cytosorbents in the third quarter valued at approximately $51,000. 32.87% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on CTSO shares. StockNews.com initiated coverage on shares of Cytosorbents in a research report on Wednesday, January 29th. They set a “hold” rating for the company. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Cytosorbents currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $0.99 on Wednesday. The business’s fifty day moving average price is $0.96 and its two-hundred day moving average price is $1.04. Cytosorbents Co. has a fifty-two week low of $0.70 and a fifty-two week high of $1.59. The stock has a market capitalization of $54.04 million, a price-to-earnings ratio of -2.75 and a beta of 0.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The firm had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. During the same period last year, the company earned ($0.21) EPS. As a group, analysts predict that Cytosorbents Co. will post -0.3 EPS for the current fiscal year.

Cytosorbents Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.